dc.creator | Herzig D., Suhner S., Roos J., Schurch D., Cecchini L., Nakas C.T., Weiss S., Kadner A., Kocher G.J., Guensch D.P., Wilinska M.E., Raabe A., Siebenrock K.A., Beldi G., Gloor B., Hovorka R., Vogt A.P., Bally L. | en |
dc.date.accessioned | 2023-01-31T08:28:09Z | |
dc.date.available | 2023-01-31T08:28:09Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.2337/dc22-0438 | |
dc.identifier.issn | 01495992 | |
dc.identifier.uri | http://hdl.handle.net/11615/73963 | |
dc.description.abstract | OBJECTIVE Perioperative management of glucose levels remains challenging. We aimed to assess whether fully closed-loop subcutaneous insulin delivery would improve glycemic control compared with standard insulin therapy in insulin-requiring patients undergoing elective surgery. RESEARCH DESIGN AND METHODS We performed a single-center, open-label, randomized controlled trial. Patients with diabetes (other than type 1) undergoing elective surgery were recruited from various surgical units and randomly assigned using a minimization schedule (stratified by HbA1c and daily insulin dose) to fully closed-loop insulin delivery with fast-acting insulin aspart (closed-loop group) or standard insulin therapy ac-cording to local clinical practice (control group). Study treatment was adminis-tered from hospital admission to discharge (for a maximum of 20 days). The primary end point was the proportion of time with sensor glucose in the target range (5.6–10.0 mmol/L). RESULTS Forty-five patients were enrolled and assigned to the closed-loop (n 5 23) or the control (n 5 22) group. One patient (closed-loop group) withdrew from the study before surgery and was not analyzed. Participants underwent abdominal (57%), vascular (23%), orthopedic (9%), neuro (9%), or thoracic (2%) surgery. The mean proportion of time that sensor glucose was in the target range was 76.7 ± 10.1% in the closed-loop and 54.7 ± 20.8% in the control group (mean difference 22.0 percentage points [95% CI 11.9; 32.0%]; P < 0.001). No episodes of severe hypoglycemia (<3.0 mmol/L) or hyperglycemia with ketonemia or any study-related adverse events occurred in either group. CONCLUSIONS In the context of mixed elective surgery, the use of fully closed-loop subcutaneous insulin delivery improves glucose control without a higher risk of hypoglycemia. © 2022 by the American Diabetes Association.. | en |
dc.language.iso | en | en |
dc.source | Diabetes Care | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137136959&doi=10.2337%2fdc22-0438&partnerID=40&md5=e81fd480b7c5bf41598e76fb3f79934e | |
dc.subject | hemoglobin A1c | en |
dc.subject | insulin aspart | en |
dc.subject | antidiabetic agent | en |
dc.subject | glucose | en |
dc.subject | human insulin | en |
dc.subject | insulin | en |
dc.subject | abdominal surgery | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | clinical article | en |
dc.subject | clinical effectiveness | en |
dc.subject | clinical practice | en |
dc.subject | controlled study | en |
dc.subject | drug effect | en |
dc.subject | drug safety | en |
dc.subject | elective surgery | en |
dc.subject | female | en |
dc.subject | glycemic control | en |
dc.subject | hemoglobin blood level | en |
dc.subject | hospital admission | en |
dc.subject | human | en |
dc.subject | hyperglycemia | en |
dc.subject | insulin dependent diabetes mellitus | en |
dc.subject | insulin treatment | en |
dc.subject | male | en |
dc.subject | neurosurgery | en |
dc.subject | orthopedic surgery | en |
dc.subject | perioperative care | en |
dc.subject | randomized controlled trial | en |
dc.subject | risk assessment | en |
dc.subject | thorax surgery | en |
dc.subject | treatment outcome | en |
dc.subject | treatment planning | en |
dc.subject | vascular surgery | en |
dc.subject | crossover procedure | en |
dc.subject | glucose blood level | en |
dc.subject | hypoglycemia | en |
dc.subject | insulin infusion | en |
dc.subject | Blood Glucose | en |
dc.subject | Cross-Over Studies | en |
dc.subject | Diabetes Mellitus, Type 1 | en |
dc.subject | Glucose | en |
dc.subject | Humans | en |
dc.subject | Hypoglycemia | en |
dc.subject | Hypoglycemic Agents | en |
dc.subject | Insulin | en |
dc.subject | Insulin Infusion Systems | en |
dc.subject | Insulin, Regular, Human | en |
dc.subject | Treatment Outcome | en |
dc.subject | American Diabetes Association Inc. | en |
dc.title | Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial | en |
dc.type | journalArticle | en |